GeoVax Labs Inc (GOVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 63

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 12
GeoVax Labs Enters into Partnership with American Gene Technologies 13
GeoVax Labs Research Agreement with Georgia State University Research Foundation 14
GeoVax Labs Enters into Research Agreement with Burnet Institute 15
GeoVax Labs Enters into Co-Development Agreement with ViaMune 16
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 17
GeoVax Labs Enters into R&D Agreement with USAMRIID 18
GeoVax Labs Enters into Research Agreement with University of Georgia 19
GeoVax Labs Enters into Research Agreement with University of Pittsburgh 20
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 21
Licensing Agreements 22
GeoVax Labs Enters into Licensing Agreement with Valneva 22
Equity Offering 23
GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 23
GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 24
GeoVax Labs Raises USD6 Million in Private Placement 25
GeoVax Labs Completes Private Placement Of Shares For US$1.6 Million 26
GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For US$2.2 Million 27
GeoVax Completes Second Tranche Of Private Placement Of Units For US$0.25 Million 28
GeoVax Labs Inc - Key Competitors 29
GeoVax Labs Inc - Key Employees 30
GeoVax Labs Inc - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 09, 2017: GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates 32
Aug 07, 2017: GeoVax Reports 2017 Second Quarter Financial Results Results and Provides Corporate Update 35
May 08, 2017: GeoVax Reports 2017 First Quarter Financial Results and Development Program Updates 37
Mar 24, 2017: GeoVax Reports 2016 Year-End Financial Results 38
Nov 11, 2016: GeoVax Reports 2016 Third Quarter Financial Results and Provides Corporate Update 39
Aug 05, 2016: GeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update 41
May 04, 2016: GeoVax Reports 2016 First Quarter Financial Results 43
Mar 16, 2016: GeoVax Reports 2015 Year-End Financial Results And Provides Corporate Update 44
Corporate Communications 45
Dec 14, 2016: GeoVax Announces Appointment of Farshad Guirakhoo, PhD as Chief Scientific Officer 45
Product News 46
12/05/2016: GeoVax to Present at Keystone Symposia on Hemorrhagic Fever Viruses 46
08/02/2016: GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials 47
07/27/2016: GeoVax Reports Progress with Hemorrhagic Fever Vaccine Program 48
06/21/2016: GeoVax Discusses Zika Vaccine Development at American Society for Virology's 35th Annual Meeting 49
06/13/2016: GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting 50
05/18/2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 51
05/02/2016: GeoVax Presents at Zika Virus Scientific Conference 52
04/18/2016: GeoVax Provides Update on Zika Vaccine Program 53
04/14/2016: GeoVax Awarded $1.4M NIH Grant 54
04/03/2017: GeoVax Awarded $658,000 NIH Grant for its HIV Vaccine Program 55
03/07/2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates 56
Feb 03, 2016: GeoVax to Develop Vaccine Against Zika Virus 57
Product Approvals 58
Jun 30, 2016: GeoVax Announces Filing of Investigational New Drug Application for HIV Human Clinical Trial 58
Clinical Trials 59
Jan 23, 2017: GeoVax Announces Initiation of HIV Human Clinical Trial 59
Oct 20, 2016: GeoVax HIV Vaccine Clinical Data Presented at HIVR4P Conference 60
Other Significant Developments 61
Mar 27, 2017: GeoVax Reports on Vaccine Development Progress 61
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
GeoVax Labs Inc, Deals By Therapy Area, 2011 to YTD 2017 9
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 12
GeoVax Labs Enters into Partnership with American Gene Technologies 13
GeoVax Labs Research Agreement with Georgia State University Research Foundation 14
GeoVax Labs Enters into Research Agreement with Burnet Institute 15
GeoVax Labs Enters into Co-Development Agreement with ViaMune 16
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 17
GeoVax Labs Enters into R&D Agreement with USAMRIID 18
GeoVax Labs Enters into Research Agreement with University of Georgia 19
GeoVax Labs Enters into Research Agreement with University of Pittsburgh 20
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 21
GeoVax Labs Enters into Licensing Agreement with Valneva 22
GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 23
GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 24
GeoVax Labs Raises USD6 Million in Private Placement 25
GeoVax Labs Completes Private Placement Of Shares For US$1.6 Million 26
GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For US$2.2 Million 27
GeoVax Completes Second Tranche Of Private Placement Of Units For US$0.25 Million 28
GeoVax Labs Inc, Key Competitors 29
GeoVax Labs Inc, Key Employees 30
GeoVax Labs Inc, Subsidiaries 31

List of Figures
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

GeoVax Labs Inc (GOVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027